Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYP688 in metastatic uveal melanoma and other GNAQ/11-mutant melanomas
NL-OMON53721Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Nov 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DYP688 in intraocular melanoma and melanoma (4 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Safety and 2 more. Started Nov 2022; status: recruiting.
02
Drugs
DYP688
03
Conditions
intraocular melanomamelanoma
Beyond the preview
Go deeper on NL-OMON53721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53721.